IPHA

Innate Pharma SA IPHA

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 10 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Revenue

$9.01M

Quarter to Dec 31

Net income

$-49.18M

Quarter to Dec 31

Free cash flow

$-52.90M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$354.0K total
Lion Point Capital, LP
$149.3K0.0%
MORGAN STANLEY
$80.1K0.0%
SmartHarvest Portfolios, LLC
$43.7KNew
XTX Topco Ltd
$27.8KNew
CITADEL ADVISORS LLC
$22.9KNew
JANE STREET GROUP, LLC
$19.0K-76.2%
RHUMBLINE ADVISERS
$8.7K-0.3%
UBS Group AG
$2.5K+58.3%
Farther Finance Advisors, LLC
$38+110.0%
GAMMA Investing LLC
$17-96.2%
See all 10 institutional holders →
Reading the latest SEC filing…

Key Metrics

Revenue

FY 2025
EDGAR

Net Income

FY 2025
EDGAR

EPS (Diluted)

FY 2025
EDGAR

Free Cash Flow

FY 2025
EDGAR

Loading ratio trend…

IPHA key financials by period

Reported revenue, net income and operating margin by fiscal year, from Innate Pharma SA's annual filings on SEC EDGAR.

Innate Pharma SA reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2025$9.0M$-49.2M—
FY 2024$20.1M$-49.5M—
FY 2023$61.6M$-7.6M-20.5%
FY 2022$57.7M$-58.1M-99.6%
FY 2021$24.7M$-52.8M-193.6%
FY 2020$69.8M$-64.0M1.6%
Source: IPHA filings on SEC EDGAR →

About Innate Pharma SA (IPHA): stock profile, AI score and financials

Innate Pharma SA (IPHA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. IPHA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 10 institutional filers currently hold this stock. Based on the latest XBRL financial filings (FY 2025), Innate Pharma SA reports quarterly revenue of $9.0M, net income of $-49.2M, free cash flow of $-52.9M. Top institutional holders of IPHA by reported 13-F value include Lion Point Capital, MORGAN STANLEY, SmartHarvest Portfolios, based on the most recent SEC filings. IPHA trades on the Nasdaq exchange and files with the SEC under CIK 1598599. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IPHA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Innate Pharma SA directly from SEC EDGAR.

SEC EDGAR: CIK 1598599 →